Open Access<p>MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma</p>
Author(s) -
Liantao Li,
Na Li,
Nianli Liu,
FuChun Huo,
Junnian Zheng
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s256226
Subject(s) - gene knockdown , cancer research , dna methylation , gene silencing , cyclin d1 , cell cycle , renal cell carcinoma , clear cell renal cell carcinoma , biology , cell growth , cancer , medicine , oncology , gene expression , cell culture , gene , biochemistry , genetics
DNA methylation plays an important role in regulating gene expression. Methyl-CpG-binding domain (MBD) proteins recognize and bind to methylated DNA, which mediate gene silencing by the interaction with deacetylases and histone methyltransferases. MBD2 has been reported in various human cancers; however, its clinical implication and potential regulatory role in renal cell carcinoma (RCC) have not been elaborated.